Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.31 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19759934 | 0.94 | KDM4E (0.41) | KDM4EATML3MBTL1PTGER4 | |
| SCHEMBL19735638 | 0.92 | KDM4E (0.41) | KDM4EATML3MBTL1PTGER4HDAC4 | |
| SCHEMBL19759887 | 0.91 | KDM4E (0.38) | KDM4EATML3MBTL1KMT2A | |
| SCHEMBL19759935 | 0.91 | KDM4E (0.40) | KDM4EATML3MBTL1PTGER4 | |
| SCHEMBL19735657 | 0.91 | KDM4E (0.40) | KDM4EATML3MBTL1PTGER4MEN1 | |
| SCHEMBL19759936 | 0.91 | KDM4E (0.40) | KDM4EATML3MBTL1PTGER4MEN1 | |
| SCHEMBL19735671 | 0.90 | KDM4E (0.42) | KDM4EATML3MBTL1HDAC4MEN1 | |
| SCHEMBL19735640 | 0.89 | KDM4E (0.31) | KDM4EATML3MBTL1 | |
| SCHEMBL20086882 | 0.89 | L3MBTL1 (0.45) | KDM4EATML3MBTL1PTGER4HDAC4 | |
| SCHEMBL22172906 | 0.88 | KDM4E (0.39) | KDM4EATML3MBTL1HDAC4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9960357-B2 | Spiro-type compound and organic light emitting element comprising same | LG CHEM, LTD. (KR) | 2018-05-01 | — | — | US | disclosed |
| US-9960357-B2 | Spiro-type compound and organic light emitting element comprising same | LG CHEM, LTD. (KR) | 2018-05-01 | — | — | US | disclosed |
| US-20170365787-A1 | SPIRO-TYPE COMPOUND AND ORGANIC LIGHT EMITTING ELEMENT COMPRISING SAME | LG CHEM, LTD. (KR) | 2017-12-21 | — | — | US | disclosed |
| US-20170365787-A1 | SPIRO-TYPE COMPOUND AND ORGANIC LIGHT EMITTING ELEMENT COMPRISING SAME | LG CHEM, LTD. (KR) | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170365787-A1 | SPIRO-TYPE COMPOUND AND ORGANIC LIGHT EMITTING ELEMENT COMPRISING SAME | CRY1, NR2E3, LEF1 | KDM4E 3359/4885ATM 1650/4885L3MBTL1 3362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.